CD40 and neoplasm: CD40 agonist promotes the antitumor activity of a variety of immune-based therapeutic strategies and may do so by engaging DCs, promoting anti-tumor TAMs, and creating a TME that is conducive to anti-tumor cytolytic effector T cells.